Icon (ICLR – Research Report) received a Hold rating and price target from Goldman Sachs analyst Matthew Sykes today. The company’s shares ...

Baird analyst Eric Coldwell lowered the firm’s price target on Icon (ICLR) to $203 from $221 and keeps a Neutral rating on the shares. The firm ...

Lekha Gupta Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00 ...

ICON Equity Income Fund earns an Average Process Pillar rating. The leading factor in the rating is the firm's retention rate of the firm's portfolio managers, which is 100% over the available ...

ICON Natural Resources and Infras Fd earns an Above Average Process Pillar rating. The largest contributor to the rating is the fund's strong long-term risk-adjusted performance. This can be seen ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Icon PLC (ICLR) came out with quarterly earnings of $3.43 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $3.46 per share a year ago. These figures ...

According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $279.17. ICON Public Limited Company, a clinical research ...